Summary of laboratory data and clinical course in 9 patients with PNH at the previous analysis and the current analysis
Patient . | Sex/age (y) . | Laboratory data (Previous/current) . | Clinical course . | ||||||
---|---|---|---|---|---|---|---|---|---|
Hb (g/dL) . | WBC (/μL) . | PMN (/μL) . | (CD59−PMN) (/μL) . | Plt (× 109/L) . | LDH (U/L) . | Duration (y) . | . | ||
J4 | F | 7.8 | 6300 | 5090 | 2545 | 313 | 1840 | 11 | P |
56 | 9.4 | 5610 | 3574 | 3503 | 214 | 4342 | P | ||
J5 | M | 12.3 | 6500 | 3835 | 2453 | 198 | 3260 | 8 | P |
39 | 8.5 | 5100 | 3162 | 3067 | 194 | 1830 | P | ||
J3 | F | 6.9 | 3100 | 1783 | 1730 | 270 | 4359 | 11 | P |
53 | 8.0 | 3400 | 2108 | 1960 | 271 | 2281 | P | ||
J11 | M | 4.6 | 1870 | 822 | 652 | 128 | 1084 | 12 | A-P |
46 | 3.8 | 1820 | 791 | 649 | 108 | 1785 | A-P | ||
J13 | F | 7.8 | 2900 | 1102 | 758 | 289 | 4872 | 8 | P |
69 | 4.9 | 2600 | 468 | 342 | 333 | 2816 | P | ||
J19 | M | 11.5 | 5780 | 3109 | 2425 | 248 | 2423 | 14 | P |
70 | 9.0 | 5130 | 1615 | 985 | 288 | 1689 | P | ||
J12 | M | 10.5 | 4930 | 3879 | 3646 | 175 | 862 | 17 | A-P → P |
50 | 13.5 | 5010 | 3181 | 1050 | 118 | 383 | P | ||
J15 | M | 7.1 | 3460 | 1647 | 1631 | 109 | 2772 | 31 | P |
58 | 4.2 | 1830 | 805 | 459 | 59 | ND | PA | ||
J16 | F | 7.5 | 4400 | 2948 | 2889 | 90 | 5364 | 24 | A → P |
62 | 5.8 | 1900 | 1178 | 507 | 7 | 287 | PA |
Patient . | Sex/age (y) . | Laboratory data (Previous/current) . | Clinical course . | ||||||
---|---|---|---|---|---|---|---|---|---|
Hb (g/dL) . | WBC (/μL) . | PMN (/μL) . | (CD59−PMN) (/μL) . | Plt (× 109/L) . | LDH (U/L) . | Duration (y) . | . | ||
J4 | F | 7.8 | 6300 | 5090 | 2545 | 313 | 1840 | 11 | P |
56 | 9.4 | 5610 | 3574 | 3503 | 214 | 4342 | P | ||
J5 | M | 12.3 | 6500 | 3835 | 2453 | 198 | 3260 | 8 | P |
39 | 8.5 | 5100 | 3162 | 3067 | 194 | 1830 | P | ||
J3 | F | 6.9 | 3100 | 1783 | 1730 | 270 | 4359 | 11 | P |
53 | 8.0 | 3400 | 2108 | 1960 | 271 | 2281 | P | ||
J11 | M | 4.6 | 1870 | 822 | 652 | 128 | 1084 | 12 | A-P |
46 | 3.8 | 1820 | 791 | 649 | 108 | 1785 | A-P | ||
J13 | F | 7.8 | 2900 | 1102 | 758 | 289 | 4872 | 8 | P |
69 | 4.9 | 2600 | 468 | 342 | 333 | 2816 | P | ||
J19 | M | 11.5 | 5780 | 3109 | 2425 | 248 | 2423 | 14 | P |
70 | 9.0 | 5130 | 1615 | 985 | 288 | 1689 | P | ||
J12 | M | 10.5 | 4930 | 3879 | 3646 | 175 | 862 | 17 | A-P → P |
50 | 13.5 | 5010 | 3181 | 1050 | 118 | 383 | P | ||
J15 | M | 7.1 | 3460 | 1647 | 1631 | 109 | 2772 | 31 | P |
58 | 4.2 | 1830 | 805 | 459 | 59 | ND | PA | ||
J16 | F | 7.5 | 4400 | 2948 | 2889 | 90 | 5364 | 24 | A → P |
62 | 5.8 | 1900 | 1178 | 507 | 7 | 287 | PA |
Nine patients were subdivided into 3 groups: increased (J4, J5); stable (J3, J11, J13, J19); and decreased (J12, J15, J16).
In each patient, the previous laboratory data and the clinical diagnosis were described in the upper row, and the current laboratory data and the clinical diagnosis were described in the lower row.
M indicates Male; F, Female; Hb, hemoglobin; WBC, white blood cell; Plt, platelet; LDH, lactate dehydrogenase; Duration, the period between the diagnosis and the current analysis; P, PNH; A-P, AA-PNH syndrome; A, aplastic anemia; ND, not done; PA, PNH aplasia.